Summary & Overview
HCPCS J9064: Cabazitaxel (Sandoz) Injection, 1 mg
HCPCS Level II code J9064 designates a 1 mg unit of cabazitaxel (Sandoz) injection and is explicitly described as not therapeutically equivalent to J9043. This code is used for billing the chemotherapeutic agent cabazitaxel when administered in outpatient infusion settings, most commonly in hospital outpatient departments and dedicated infusion centers. Nationally, accurate coding for oncology drugs like cabazitaxel affects reimbursement, inventory management, and drug-specific utilization tracking.
Key payers included in this review are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The content outlines payer coverage patterns and the clinical and billing context relevant to infusion of cabazitaxel, focusing on unit-based drug coding and the implications of non-equivalence to other cabazitaxel codes.
Readers will find benchmarks and practical reference points on code definition and typical site-of-service application, a concise summary of common modifiers used with oncology drug administration (input provided), and a national policy context affecting drug billing and documentation. Where specific input data is missing, the publication notes that data are not available in the input. The summary is intended for billing managers, oncology clinicians involved in coding, and policy analysts monitoring chemotherapy reimbursement and coding consistency.
Billing Code Overview
HCPCS Level II code J9064 represents an injection of cabazitaxel (Sandoz), billed per 1 mg unit and noted as not therapeutically equivalent to J9043. This code denotes administration of the cabazitaxel drug product supplied by Sandoz.
Service Type: Drug administration / chemotherapy infusion
Typical Site of Service: Hospital outpatient department or infusion center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male with metastatic castration-resistant prostate cancer who has progressed after prior chemotherapy with docetaxel and androgen receptor–targeted therapy. The oncology practice schedules an outpatient infusion visit for administration of cabazitaxel. The dose is calculated per body surface area and prepared by the infusion pharmacy as J9064 (cabazitaxel, 1 mg). Prior to treatment, the patient undergoes standard pre‑infusion assessment: review of recent labs (complete blood count, liver function tests), performance status check, review of concomitant medications and prior hypersensitivity history, and verification of consent and treatment plan. Antiemetic premedication and growth factor support are ordered per protocol. On the day of service the patient is registered, identity and chemotherapy order are verified using two identifiers, the drug is administered via intravenous infusion by an oncology-certified nurse in the infusion suite (typical outpatient hospital outpatient department or independent oncology infusion center), and the patient is observed for infusion‑related reactions. Post‑infusion documentation includes drug name and HCPCS code J9064, dose administered (mg), lot number, infusion start and end times, any modifiers as applicable, and instructions for follow‑up dosing and toxicity monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |